GeneDx Holdings (WGS) Cash & Current Investments (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Cash & Current Investments data on file, last reported at $170.7 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $170.7 million, up 7.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $170.7 million (up 7.24% YoY), and the FY2025 annual result was $171.3 million, up 21.32% from the prior year.
• Cash & Current Investments steadied at $170.7 million in Q1 2026 per WGS's latest filing, from $171.3 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $315.0 million in Q1 2022 and troughed at $106.9 million in Q2 2024.
• A 5-year average of $164.6 million and a median of $155.1 million in 2025 frame the typical range for Cash & Current Investments.
• On a YoY basis, Cash & Current Investments climbed as much as 973.92% in 2022 and fell as far as 69.06% in 2022.
• A 5-year view of Cash & Current Investments shows it stood at $123.9 million in 2022, then climbed by 5.01% to $130.1 million in 2023, then gained by 8.48% to $141.2 million in 2024, then grew by 21.32% to $171.3 million in 2025, then dropped by 0.35% to $170.7 million in 2026.
• Business Quant data shows WGS's Cash & Current Investments at $170.7 million in Q1 2026, $171.3 million in Q4 2025, and $155.1 million in Q3 2025.